BeOne Medicines Announces $950M IMDELLTRA Royalty Deal
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty...
Category : Clinical Research, Pharma & Healthcare Financing
Uveal Melanoma Market Insights and Outlook to 2034 | DelveInsight
The uveal melanoma market is small but strategically important, driven by significant unmet medical needs, few available treatments, and growing innovation. Targeted therapies and immunotherapies,...
Sensory Cloud Shows Positive Phase 2a Results for Chronic Cough
Daily treatment with SC0023 yielded treatment efficacy 53.5% ± 19.2% relative to baseline in 24-hour daily cough rate and 19.5% ± 6.2% placebo effect Cough...
Circle Pharma Publishes Anti-Tumor Study in Nature Journal
Research uncovers how inhibiting interactions between cyclin A and cyclin B and their key binding partners, E2F and MYT1, selectively kills E2F-high tumor cells Circle...
Myosin Therapeutics Wins $4.5M Grant for Glioblastoma Trial
Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer...
First Patient Dosed in Phase III Cadonilimab Trial for Gastric CA
Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating...
GoodRx, Novo Nordisk Offer Ozempic, Wegovy at $499/Month
Until today, Ozempic® has not been available to eligible self-paying patients at this price GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today...
PharmaCyte Biotech Raises $7M from Existing Investors
PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing with...
MedImpact Offers Low-Cost Ustekinumab Biosimilar
MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara® (ustekinumab). The...
FDA Clears VASTHERA to Begin Trial for PAH Drug VTB-10
On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)...
VantagePoint AI Flags UNH Stock Trends Before Buffett Move
Advanced technical indicators provided early warning signals before major market developments Vantagepoint A.I., LLC, a leading provider of artificial intelligence-driven market forecasting technology, announced today...
GC Biopharma, Thai Red Cross Partner on Plasma Therapies
GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed a Memorandum of Understanding (MOU) with the Thai Red Cross Society...
pH-D Begins FDA-Cleared Phase 3 Boric Acid Trial
pH-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug...
Provident Advises Elder Care on Rallyday Partnership
Provident Healthcare Partners (“Provident”), a leading healthcare investment banking firm, is pleased to announce its role as exclusive financial advisor to Elder Care Homecare (“Elder Care”)...
Telitacicept Hits Phase III Goal for Sjögren’s in China
On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical...